Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double-blind, Fixed Multiple Dose, Randomised, Placebo-controlled,Multicentre Clinical Trial.

NCT01824602 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT01824602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double-blind, Fixed Multiple Dose, Randomised, Placebo-controlled,Multicentre Clinical Trial.
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2006
Completion date
November 30, 2006
Enrollment
38 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder